U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drives home the urgent need to pass robust drug pricing reforms.”
U.S. Senate Finance Committee Chair Ron Wyden (D-Ore.) said this week that new Congressional Budget Office (CBO) findings on brand drug price increases “drives home the urgent need to pass robust drug pricing reforms.”
*Sign up for news summaries and alerts from 340B Report